Benzinga | Sep 23, 2021 04:10PM EDT

Paratek To Present New Data For NUZYRA At IDWeek 2021 Wednesday, Sept. 29

Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infections

BOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced today that data from the NUZYRA(r) (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting.

Poster presentations will be available beginning on Wednesday, Sept. 29 in the IDWeek ePoster Gallery.

Presentation Title: Incidence of C. difficile infection (CDI) Cases by CDI-Standardized Infection Ratio (SIR) Among Centers for Medicare & Medicaid Services (CMS)-Participating Short-Term Acute Care Hospitals (ACH) Post Implementation of the Hospital-Acquired Condition Reduction Program (HAC-RP)

Poster #: 767

Presenter: Thomas P. Lodise, PharmD, Ph.D.

Presentation Title: Omadacycline in Vitro Activity Against Bacillus Anthracis

Poster #: 1208

Presenter: Alisa W. Serio, Ph.D.

Presentation Title: Comparison of Healthcare Resource Utilization (HRU) Among Adult Patients Treated with Omadacycline (OMC) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) or Community-Acquired Bacterial Pneumonia (CABP) in the 30 Day Pre- and Post-OMC Prescription (Rx)

Poster #: 1372

Presenter: Thomas P. Lodise, PharmD, Ph.D.

In addition, two investigator-initiated studies involving NUZYRA will be presented:

Presentation Title: Efficacy of Germinants and Omadacycline for Preventing Clostridioides difficile Relapse in a Murine Model

Poster #: 1037

Presenter: Noah Budi, PharmD

Presentation Title: Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation

Poster #: 1082

Presenter: Taylor Morrisette, PharmD

"With these presentations, Paratek continues to deepen the understanding of the utility of NUZYRA for serious community-acquired infections and nontuberculous mycobacterial infections, a rare disease for which there are no approved therapies," said Randy Brenner, Chief Development & Regulatory Officer of Paratek. "Notably, we will share the results of two studies examining the potential of NUZYRA in treating anthrax infections, one of the agents most likely to be used in a bioterrorism attack, and a health economics study examining healthcare resource utilization among patients treated with NUZYRA for skin infections and pneumonia."